STIMNeuronetics, Inc.

Greenbrook revenue surged 16.8% while NeuroStar transitions to new commercial models.

Moby summary of Neuronetics, Inc.'s Q2 2026 earnings call

Neuronetics Inc (STIM) reports 9.1% revenue growth and positive adjusted EBITDA, signaling a strong turnaround in Q2 2026.

Neuronetics (NASDAQ:STIM) reported second-quarter 2026 revenue growth, a sharply narrower net loss and positive adjusted EBITDA as its Greenbrook clinic business expanded and the company introduced additional commercial purchasing options for its NeuroStar transcranial magnetic stimulation, or TMS,

Neuronetics improved margins, reached positive adjusted EBITDA and lowered its 2026 operating expense outlook, although NeuroStar revenue declined during the quarter. Key Investor TakeawaysNeuronetics (NASDAQ:STIM) reported second-quarter revenue of $41.

Neuronetics (STIM) delivered earnings and revenue surprises of +54.55% and +3.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BWAY earns Bull of the Day on expanding Deep TMS adoption, while LULU lands Bear of the Day as slowing growth and falling estimates weigh on outlook.

Brainsway shares have rallied more than 60% this year, with more bullish tailwinds at its back.

Neuronetics, Inc. (NASDAQ:STIM) is one of the 10 High Growth Stocks Insiders Are Buying. On July 6, 2026, Neuronetics, Inc. (NASDAQ:STIM) announced that management will participate at B. Riley Securities’ Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in person at the InterContinental Boston. Neuronetics will participate in a panel discussion titled […]

Neuronetics (NASDAQ:STIM) reported first-quarter 2026 results that management said were largely in line with expectations, as the company balanced growth in its Greenbrook clinic business with a slight decline in overall NeuroStar revenue. President and CEO Dan Reuvers, who led his first earnings ca